Adjunctive effects of orthokeratology and atropine 0.01% eye drops on slowing the progression of myopia

References

• Vitale S, Sperduto RD, Ferris FL 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol. 2009;127:1632–1639.
   PubMedGoogle Scholar
• Li SM, Li SY, Liu LR, et al. Peripheral refraction in 7- and 14-year-old children in central China: the anyang childhood eye study. Br J Ophthalmol. 2015;99:674–679.
   PubMed Web of Science ®Google Scholar
• Lin LL, Shih YF, Tsai CB, et al. Epidemiologic study of ocular refraction among schoolchildren in Taiwan in 1995. Optom Vis Sci. 1999;76:275–281.
   PubMed Web of Science ®Google Scholar
• Saw SM, Gazzard G, Shih-Yen EC, et al. Myopia and associated pathological complications. Ophthalmic Physiol Opt. 2005;25:381–391.
   PubMed Web of Science ®Google Scholar
• Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123:697–708.
   PubMed Web of Science ®Google Scholar
• Cho P, Cheung SW, Edwards M. The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res. 2005;30:71–80.
   PubMed Web of Science ®Google Scholar
• Hiraoka T, Kakita T, Okamoto F, et al. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a five-year follow-up study. Invest Ophthalmol Vis Sci. 2012;53:3913–3919.
   PubMed Web of Science ®Google Scholar
• Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285–2291.
   PubMed Web of Science ®Google Scholar
• Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347–354.
   PubMed Web of Science ®Google Scholar
• Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126:113–124.
   PubMed Web of Science ®Google Scholar
• Yam JC, Li FF, Zhang X, et al. Two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: phase 2 report. Ophthalmology. 2020;127:910–919.
   PubMed Web of Science ®Google Scholar
• Kang P, Swarbrick H. Peripheral refraction in myopic children wearing orthokeratology and gas-permeable lenses. Optom Vis Sci. 2011;88:476–482.
   PubMed Web of Science ®Google Scholar
• Gallego P, Martinez-Garcia C, Perez-Merino P, et al. Scleral changes induced by atropine in chicks as an experimental model of myopia. Ophthalmic Physiol Opt. 2012;32:478–484.
   PubMed Web of Science ®Google Scholar
• Chen Z, Huang S, Zhou J, et al. Adjunctive effect of orthokeratology and low dose atropine on axial elongation in fast-progressing myopic children-A preliminary retrospective study. Cont Lens Anterior Eye. 2019;42:439–442.
   PubMed Web of Science ®Google Scholar
• Kinoshita N, Konno Y, Hamada N, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a two-year randomised trial. Sci Rep. 2020;10:12750.
   PubMed Web of Science ®Google Scholar
• Maseedupally VK, Gifford P, Lum E, et al. Treatment zone decentration during orthokeratology on eyes with corneal toricity. Optom Vis Sci. 2016;93:1101–1111.
   Web of Science ®Google Scholar
• Soni PS, Nguyen TT, Bonanno JA. Overnight orthokeratology: refractive and corneal recovery after discontinuation of reverse-geometry lenses. Eye Contact Lens. 2004;30:254–262. discussion 263-254.
   PubMedGoogle Scholar
• Cho P, Cheung SW. Retardation of myopia in orthokeratology (ROMIO) study: a two-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012;53:7077–7085.
   PubMed Web of Science ®Google Scholar
• Li SM, Kang MT, Wu SS, et al. Efficacy, safety and acceptability of orthokeratology on slowing axial elongation in myopic children by meta-analysis. Curr Eye Res. 2016;41:600–608.
   PubMed Web of Science ®Google Scholar
• Larkin GL, Tahir A, Epley KD, et al. Atropine 0.01% eye drops for myopia control in American children: a multiethnic sample across three US sites. Ophthalmol Ther. 2019;8:589–598.
   PubMed Web of Science ®Google Scholar
• Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on axial elongation in childhood myopia. Invest Ophthalmol Vis Sci. 2011;52:2170–2174.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Chen Z, Xue F, et al. Central and peripheral corneal power change in myopic orthokeratology and its relationship with two-year axial length change. Invest Ophthalmol Vis Sci. 2015;56:4514–4519.
   PubMed Web of Science ®Google Scholar
• Kinoshita N, Konno Y, Hamada N, et al. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol. 2018;62:544–553.
   PubMed Web of Science ®Google Scholar
• Queiros A, Lopes-Ferreira D, Yeoh B, et al. Refractive, biometric and corneal topographic parameter changes during 12 months of orthokeratology. Clin Exp Optom. 2020;103:454–462.
   PubMed Web of Science ®Google Scholar
• Thorn F, Gwiazda J, Held R. Myopia progression is specified by a double exponential growth function. Optom Vis Sci. 2005;82:286–297.
   PubMed Web of Science ®Google Scholar
• Chen Z, Niu L, Xue F, et al. Impact of pupil diameter on axial growth in orthokeratology. Optom Vis Sci. 2012;89:1636–1640.
   PubMed Web of Science ®Google Scholar
• Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, et al. Short-term changes in ocular biometry and refraction after discontinuation of long-term orthokeratology. Eye Contact Lens. 2014;40:84–90.
   PubMed Web of Science ®Google Scholar
• Yang L, Guo X, Xie P. Observation of orthokeratology discontinuation. Zhonghua Yan Ke Za Zhi. 2015;51:178–182.
   Google Scholar